ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Annexon Inc

Annexon Inc (ANNX)

6.24
0.065
(1.05%)
Closed July 26 4:00PM
6.25
0.01
(0.16%)
After Hours: 6:00PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
6.25
Bid
5.81
Ask
6.39
Volume
1,180,264
6.1029 Day's Range 6.45
1.57 52 Week Range 8.40
Market Cap
Previous Close
6.175
Open
6.25
Last Trade Time
Financial Volume
$ 7,368,354
VWAP
6.243
Average Volume (3m)
3,024,562
Shares Outstanding
92,412,866
Dividend Yield
-
PE Ratio
-4.30
Earnings Per Share (EPS)
-1.45
Revenue
-
Net Profit
-134.24M

About Annexon Inc

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmu... Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Annexon's product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; and ANX009, for systemic autoimmune diseases. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Annexon Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ANNX. The last closing price for Annexon was $6.18. Over the last year, Annexon shares have traded in a share price range of $ 1.57 to $ 8.40.

Annexon currently has 92,412,866 shares outstanding. The market capitalization of Annexon is $570.65 million. Annexon has a price to earnings ratio (PE ratio) of -4.30.

Annexon (ANNX) Options Flow Summary

Overall Flow

Bullish

Net Premium

112k

Calls / Puts

100.00%

Buys / Sells

100.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

ANNX Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.529.075043630025.736.455.4612316905.9385995CS
41.4229.39958592134.836.454.4518567955.45272457CS
121.531.57894736844.757.444.230245625.55171747CS
261.6535.86956521744.68.43.8622677215.63143749CS
523.0192.90123456793.248.41.5714428955.14688373CS
156-14.8-70.308788598621.0523.611.577682195.42309364CS
260-10.6135-62.937705695716.863538.011.576169246.77982335CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
WINTWindtree Therapeutics Inc
$ 8.24
(150.46%)
48.57M
BFIBurgerFi International Inc
$ 0.4206
(97.37%)
313.59M
NBSTWNewbury Street Acquisition Corporation
$ 0.1349
(92.71%)
122.1k
YIBOPlanet Image International Ltd
$ 2.915
(53.43%)
260.07k
CREVCarbon Revolution Public Ltd
$ 9.00
(45.87%)
8.06M
NMHINatures Miracle Holding Inc
$ 0.2035
(-48.06%)
7.69M
TANHTantech Holdings Ltd
$ 0.2585
(-47.23%)
6.75M
DXCMDexCom Inc
$ 64.00
(-40.66%)
53.92M
PSIGPS International Group Ltd
$ 1.42
(-31.40%)
716.26k
POAIPredictive Oncology Inc
$ 1.36
(-27.27%)
6.02M
SLNASelina Hospitality PLC
$ 0.0305
(-18.88%)
408.45M
BFIBurgerFi International Inc
$ 0.4206
(97.37%)
313.59M
NVDANVIDIA Corporation
$ 113.06
(0.69%)
293.33M
SQQQProShares UltraPro Short QQQ
$ 9.10
(-2.88%)
176.49M
SGMOSangamo Therapeutics Inc
$ 0.8612
(28.15%)
123.71M

ANNX Discussion

View Posts
tw0122 tw0122 2 months ago

Item?8.01.
Other Events.
On June 4, 2024, Annexon announced positive topline results from a randomized placebo-controlled pivotal Phase 3 clinical trial in patients with GBS. The Phase 3 trial met its primary endpoint, with a single infusion of ANX005 30 mg/kg achieving a statistically significant 2.4-fold improvement on the GBS-disability scale (“GBS-DS”) (proportional odds analysis, week 8, p = 0.0058). ANX005 30 mg/kg treatment also demonstrated improvements versus placebo on key secondary endpoints, including early gains in muscle strength (day 8, p < 0.0001* and week 8, p = 0.0351*) and a median of 28 fewer days on artificial ventilation (through week 26, p = 0.0356*). Additionally, ANX005 30 mg/kg demonstrated an early reduction in the prespecified analysis of serum levels of neurofilament light chain, a biomarker of nerve damage (11.2% reduction relative to placebo between weeks 2–4, p = 0.03*) and a 31-day reduction in the median time to walk independently (week 26, p = 0.0211*), each of which are important clinical care outcomes. (* nominal)
The randomized, placebo-controlled Phase 3 trial, which enrolled 241 subjects in Bangladesh and the Philippines, evaluated two doses of ANX005, 30 mg/kg and 75 mg/kg, which both delivered rapid and complete suppression of complement activity but differed in duration of C1q inhibition. The 30 mg/kg dose lasted one week and the 75 mg/kg dose lasted two to three weeks. ANX005 75 mg/kg outperformed placebo on multiple endpoints, however, it was not statistically significant on the primary endpoint of GBS-DS at week 8 (p = 0.5548). The two dose levels were evaluated based on findings in the earlier Phase 1b proof-of-concept study, which showed efficacy in pooled analysis of both shorter and longer duration of ANX005 C1q inhibition. Because classical complement drives tissue damage in the early phase of disease, while facilitating nerve repair after acute nerve injury, the strong positive Phase 3 results with the 30 mg/kg dose resulting in one week of C1q inhibition appeared to define the optimal treatment window.
The clinical safety and tolerability findings of ANX005 at both doses in the Phase 3 study support a generally well-tolerated profile with no new safety signals. The majority of adverse events were mild Grade 1 to moderate Grade 2 events. The most common treatment-related adverse events were infusion related reactions (30.4%) that were mostly mild transient rashes. There were no autoimmune related adverse events and no drug-related deaths or serious infections observed.
The GBS Phase 3 study was conducted in Bangladesh and Philippines due to the high prevalence of GBS and limited access to standard of care intravenous immunoglobulin. Based on feedback from the U.S. Food and Drug Administration (“FDA”), Annexon has initiated a real-world evidence (“RWE”) protocol with International Guillain-Barré Syndrome Outcomes Study to establish comparability between Phase 3 participants and Western patients. RWE data and a potential biologics license application submission with the FDA are expected in the first half of 2025. Annexon plans to present the Phase 3 data at the 2024 Peripheral Nerve Society Annual Meeting on June 25, 2024.
GBS is a rapid and acute neurological disease with a narrow therapeutic window that results in the hospitalization of over 22,000 people annually in the U.S. and Europe. The significant and long-term disease burden associated with GBS on patients, caregivers, hospitals and payers has led to a multi-billion-dollar annual economic cost to the U.S. healthcare system. Currently, there are no approved treatments for GBS by the FDA.
Item?9.01.
Financial Statements and Exhibits.
👍️0
Monksdream Monksdream 3 months ago
ANNX under $5
👍️0
JohnCM JohnCM 4 months ago
Looking good!
👍️0
Monksdream Monksdream 4 months ago
ANNX new 52 hi
👍️0

Your Recent History

Delayed Upgrade Clock